Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / RNF113A



This biomarker is also known as:
  • RING finger protein 113A,
  • zinc finger protein 183 (RING finger, C3HC4 type),
  • RNF113,
  • Zinc finger protein 183,
  • Cwc24,
  • ring finger protein 113A,
  • ZNF183,

View in BioMuta


RNF113A is a member of the RNF family, or RING-type zinc finger proteins. The RNF proteins are a subset of the larger family of zinc finger proteins. Members of the RNF family have an enzyme activity known as E3 ubiquitin-protein ligase which targets other proteins to be degraded within cells. RNF113A contains a C3H1-type zinc finger domain and a C3HC4 Ring-type (Really Interesting New Gene-type) zinc finger domain. The Ring-type zinc finger domain is present in various tumor suppressors, DNA repair genes and cytokine receptor-associated molecules, and is implicated in mediating protein-protein interactions.


QA State: Curated
Type: Protein
Short Name:
HGNC Name: RNF113A


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Under Review


RNF113A is a RING-type zinc finger protein. Several RING-type zinc finger proteins act as tumor suppressors. BRCA1 is also a RING-type zinc finger protein, with the same C3HC4 Ring-type zinc finger domain as RNF113A. Mutations in the tumor suppressor BRCA1 are widely known to contribute to the development of breast cancer.

Performance Comment

RNF113A was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.